Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Canada
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
1. 3-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea
2. Cariprazine
3. Cariprazine Hcl
4. N'-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-n,n-dimethylurea Monohydrochloride
5. Rgh-188
6. Trans-4-(2-(4-(2,3-dichlorophenyl)piperazine-1-yl)-ethyl)-n,n-dimethylcarbamoyl-cyclohexyl-amine Hydrochloride
7. Vraylar
1. 1083076-69-0
2. Cariprazine Hcl
3. Vraylar
4. Rgh188 Hydrochloride
5. Rgh-188 Hcl
6. Cariprazine (hydrochloride)
7. Cariprazine Hydrochloride [usan]
8. Kqd7c255yg
9. Mfcd26142670
10. 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea;hydrochloride
11. Unii-kqd7c255yg
12. Cariprazine.hcl
13. Vraylar (tn)
14. Cariprazine Hydrochloride (jan/usan)
15. Cariprazine Monohydrochloride
16. Schembl183803
17. Schembl183804
18. Chembl2024517
19. Chebi:90932
20. Dtxsid101026486
21. Bcp24194
22. Ex-a1644
23. Hy-14763a
24. S5849
25. Cariprazine Hydrochloride [mi]
26. Cariprazine Hydrochloride [jan]
27. Cs-1570
28. Sb16840
29. 3-[trans-4-[2-[4-(2,3-dichlorophenyl)-1-piperazinyl]ethyl]cyclohexyl]-1,1-dimethylurea Hydrochloride
30. Ac-33130
31. Cariprazine Hydrochloride [who-dd]
32. Sy039271
33. Ft-0701196
34. A15036
35. Cariprazine Hydrochloride [orange Book]
36. D09876
37. A857936
38. Q27162922
39. 3-((1r,4r)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea Hydrochloride
40. N'-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-n,n-dimethylurea Monohydrochloride
41. N'-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-n,n-dimthylurea Monohydrochloride
42. N'-(trans-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexyl)-n,n-dimethylurea Hydrochloride
43. N'-[trans-4-[2-[4-(2,3-dichlorophenyl)-1-piperazinyl]ethyl]cyclohexyl]-n,n-dimethylurea Hydrochloride
44. Urea, N'-(trans-4-(2-(4-(2,3-dichlorophenyl)-1-piperazinyl)ethyl)cyclohexyl)-n,n- Dimethyl-, Hydrochloride (1:1)
Molecular Weight | 463.9 g/mol |
---|---|
Molecular Formula | C21H33Cl3N4O |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 462.171995 g/mol |
Monoisotopic Mass | 462.171995 g/mol |
Topological Polar Surface Area | 38.8 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 491 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Reagila is indicated for the treatment of schizophrenia in adult patients.
Treatment of schizophrenia
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
N05AX15
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33846
Submission : 2019-05-30
Status : Active
Type : II
Hubei Gedian Humanwell focuses on R&D, production, & sales of fertility regulation drugs & steroidal APIs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26321
Submission : 2012-07-26
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-14
Pay. Date : 2023-09-27
DMF Number : 38933
Submission : 2023-09-26
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-07-31
Pay. Date : 2019-07-18
DMF Number : 33834
Submission : 2019-07-18
Status : Active
Type : II
Date of Issue : 2022-08-08
Valid Till : 2025-07-14
Written Confirmation Number : WC-0168
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33399
Submission : 2018-12-14
Status : Active
Type : II
NDC Package Code : 14501-0035
Start Marketing Date : 2018-12-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?